2-Bromo-?-ergocryptine
Parkinsonian Disorder
Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Institute of Liver and Biliary Sciences, India
Modality
Small molecule
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02265484CT.gov To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinsonian Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 2-Bromo-?-ergocryptine (this asset) | Institute of Liver and Biliary Sciences, India | N/A | D · 30 |
| .Beta.-Cit | Institute for Neurodegenerative Disorders | P2 | BBB |
| Ioflupane | GE Healthcare | P3 | BB |
| 8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)- | Alseres Pharmaceuticals, Inc | P3 | B |
| Levodopa | Institute for Neurodegenerative Disorders | P2 | B |
| Pramipexole | Institute for Neurodegenerative Disorders | P2 | B |
| Carbidopa | Institute for Neurodegenerative Disorders | N/A | D |
| Rifaximin | Institute of Liver and Biliary Sciences, India | N/A | D |
| Lactulose | Institute of Liver and Biliary Sciences, India | N/A | D |
+2 more in the Parkinsonian Disorder cohort
Other indications for 2-Bromo-?-ergocryptine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Parkinson Disease | — | P4 | BB · 69 |
| Prediabetes Syndrome | — | P4 | BB · 65 |
| Eating Disorder | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- .Beta.-CitInstitute for Neurodegenerative DisordersBBB
- IoflupaneGE HealthcareBB
- 8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)-Alseres Pharmaceuticals, IncB
- LevodopaInstitute for Neurodegenerative DisordersB
- PramipexoleInstitute for Neurodegenerative DisordersB
Citation
Floatz Terminal. 2-Bromo-?-ergocryptine in Parkinsonian Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-bromo-ergocryptine-parkinsonian-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →